eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2020
vol. 37
 
Share:
Share:
more
 
 
abstract:
Special paper

Biological drugs in the treatment of atopic dermatitis – current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine

Roman J. Nowicki
1
,
Magdalena Trzeciak
1
,
Lidia Rudnicka
2
,
Jacek Szepietowski
3
,
Marek Kulus
4
,
Maciej Kupczyk
5
,
Agnieszka Mastalerz-Migas
6
,
Jarosław Peregud-Pogorzelski
7
,
Karina Jahnz-Różyk
8
,
Joanna Narbutt
9
,
Magdalena Czarnecka-Operacz
10
,
Rafał Czajkowski
11
,
Elżbieta Grubska-Suchanek
1
,
Dorota Krasowska
12
,
Beata Kręcisz
13
,
Cezary Kowalewski
14
,
Aleksandra Lesiak
8
,
Malgorzata Olszewska
2
,
Zbigniew Samochocki
2
,
Radosław Śpiewak
15
,
Aleksandra Wilkowska
1

1.
Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland
2.
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
3.
Department of Dermatology, Venereology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
4.
Department of Pediatric Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland
5.
Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland
6.
Department of Family Medicine, Medical University of Wroclaw, Wroclaw, Poland
7.
Department of Pediatrics and Pediatric Oncology, Pomeranian Medical University, Szczecin, Poland
8.
Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Medical Institute, Warsaw, Poland
9.
Department of Dermatology, Pediatric and Oncological Dermatology, Medical University of Lodz, Lodz, Poland
10.
Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
11.
Lodz, Poland Department of Dermatology and Venereology, “Ludwik Rydygier” Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University inTorun, Poland
12.
Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland
13.
Department of Dermatology, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland
14.
Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland
15.
Department of Experimental Dermatology and Cosmetology, Jagiellonian University Medical College, Krakow, Poland
Adv Dermatol Allergol 2020; XXXVII (5): 617-624
Online publish date: 2020/11/07
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Atopic dermatitis (AD) is secondary to genetic, immunological and microbiological disorders as well as epidermal barrier defects, which are the main targets of therapy. The disease proceeds with periodic exacerbations. Its development and course are influenced by numerous environmental and individual factors. In recent decades, in industrialized countries, there has been a threefold increase in the incidence of AD. There is also an increasing number of cases resistant to topical treatment. Effective treatment of AD should provide control of clinical symptoms, prevent exacerbations and improve the quality of life of patients. The multifactorial etiopathogenesis and various endotypes and phenotypes of AD justify the tendency to optimize and personalize the therapy. Currently, we recommend the use of dupilumab for the treatment of patients from 12 years of age with moderate and severe atopic dermatitis, who do not respond to topical treatment.
keywords:

biological drugs, dupilumab, atopic dermatitis, therapeutic recommendations

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe